Candida parotitis with abscess formation

Acta Oto-Laryngologica

Volumn 126, Issue 3, 2006, Pages 334-336

  Even Tov, Ella ^a   Niv, A ^a   Kraus, M ^a   Nash, Michael ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Candida albicans; Histatins; Parotid gland

Indexed keywords

FLUCONAZOLE;

AGED; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; CULTURE MEDIUM; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; ELDERLY CARE; HUMAN; INCISION; MALE; PAROTID GLAND ABSCESS; PAROTITIS; PATHOGENESIS; PRIORITY JOURNAL; PUS; SURGICAL DRAINAGE;

ABSCESS; ACUTE DISEASE; AGED; CANDIDA ALBICANS; CANDIDIASIS; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DRAINAGE; FLUCONAZOLE; FOLLOW-UP STUDIES; HUMANS; MALE; PAROTITIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 32944458123     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480500388992     Document Type: Article

References (16)

1. Ueta E, Tanida T, Doi S, Osaki T. Regulation of Candida albicans growth and adhesion by saliva. J Lab Clin Med 2000;136:66-73.
2. Krippaehne WW, Hunt TK, Dunphy JE. Acute suppurative parotitis: a study of 161 cases. Ann Surg 1962;156:251-7.
3. Raad II, Sabbadh MF, Caranasos GJ. Acute bacterial sialadenitis: a study of 29 cases and review. Rev Infect Dis 1990;12:591-601.
4. Knee TS, Ohl CA. Salmonella parotitis with abscess formation in a patient wih human immunodeficiency virus infection. Clin Infect Dis 1997;24:1009-10.
5. Bhat NA, Stansbie JM. Tuberculous parotitis: a case report. J Laryngol Otol 1996;110:976-7.
6. Pujol F, Angirekula M, Weiner M, Jindrak K, Pachter B. Parotitis due to Torulopsis glabrata. Clin Infect Dis 1995;21:1342-3.
7. Stephanopoulos PK, Karakassis DT, Triantafyllidou A. Stensen's duct obstruction by foreign body and subsequent candidal infection of the parotid gland. J Laryngol Otol 2003;117:662-5.
8. Marioni G, Rinaldi R, de Filippis C, Gaio E, Staffieri A. Candidal abscess of the parotid gland assosiated with facial nerve paralysis. Acta Otolaryngol (Stockh) 2003;123:661-3.
9. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-78.
10. Batsakis JG. Salivary glands: physiology. In: Cummings CW, editor. Otolaryngology - head and neck surgery, 3rd edn. St Louis: Mosby; 1998. p. 1210-22.
11. Edgerton M, Koshlukova SE, Lo TE, Chrzan BG, Straubinger RM, Raj PA. Candidacidal activity of salivary histatins. J Biol Chem 1998;273:20438-47.
12. Situ H, Bobek LA. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 2000;44:1485-93.
13. Koshlukova SE, Araujo MWB, Baev D, Edgerton M. Released ATP is an extracellular cytotoxic mediator in salivary histatin-5 induced killing of Candida albicans. Infect Immun 2000;68:6848-56.
14. Helmerhost EJ, Troxler RF, Oppenheim FG. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Nad Acad Sci 2001;98:14637-42.
15. Force RW, Nahata MC. Salivary concentraions of ketoconazole and fluconazole: implication for drug efficacy in oropharyngeal candidiasis. Ann Pharmocother 1995;29:10-5.
16. Kavanagh K, Dowd S. Histatins: antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 2004;56:285-9.